Only half of patients with chronic hepatitis C virus (HCV) infection experience sustained virologic response to pegylated-interferon and ribavirin, which cause numerous side effects. Thus, the identification of more effective and better tolerated agents is a high priority. We applied chemical biology to screen small molecules that regulate HCV. Methods: We first optimized the Huh7/RepFeo replicon cell line for the 384-well microplate format and used this line to screen a large library of well-characterized, known biologically active compounds using automated technology. After identifying several molecules capable of either stimulating or inhibiting HCV replication in this primary screen, we then validated our hit compounds using a full-length HCV replicon cell line in secondary screens. Results: We identified and validated a number of antiviral and proviral agents, including HMG-CoA reductase inhibitors (antiviral) and corticosteroids (proviral). The finding of increased replication associated with corticosteroids suggests that these agents directly promote viral replication independent of their suppressive effects on the immune response. The finding of antiviral activity associated with the HMG-CoA reductase inhibitors implies an important role for lipid metabolism in the viral life cycle. Conclusions: We have developed a simple, reproducible, and reliable cell-based high-throughput screening assay system using an HCV replicon model to identify small molecules that regulate HCV replication. This method can be used to identify not only putative antiviral agents, but also cellular regulators of viral replication.
H epatitis C virus (HCV) infects over 170 million people worldwide and frequently leads to cirrhosis, liver failure, and hepatocellular carcinoma. 1 The current best therapy for chronic hepatitis C is a combination of pegylated interferon (PEG-IFN) and ribavirin. Although the sustained virologic response (SVR) rate approaches 80% for patients with genotypes 2 and 3, the SVR rate is limited to about 45% for HCV genotype 1, which is responsible for about 75% of all cases of HCV in the United States. 2 Furthermore, interferon is parenteral, has an unfavorable side effect profile, and its use requires frequent monitoring for toxicity, ultimately causing 20% of patients to discontinue therapy. 2 The identification of more effective and better tolerated agents is therefore a high priority.
The advancement of our understanding of the mechanisms underlying HCV replication and persistence and the development of new antiviral therapeutics has been hampered by the lack of tractable model systems capable of robust viral replication. 3 However, the recent development of models capable of high-level autonomous HCV RNA replication has greatly facilitated the evaluation of antiviral activities of new anti-HCV drug candidates as well as the study of viral RNA replication and persistence. 4 In parallel with advances in the cultivation of HCV, chemical biology has emerged as a powerful tool to study biological processes using small organic molecules. 5, 6 In the field of chemical biology, 2 general screening approaches have been employed-reverse and forward chemical genetics. 6 Reverse chemical genetics, which has historically been used, starts with a given enzymatic or molecular target and attempts to identify small organic molecules capable of binding to it. The weakness of this approach is that not all binding interactions identified are capable of producing the desired biological effect. On the other hand, forward chemical genetics involves screening perturbagens, such as small molecules, for their effects on a given phenotypic endpoint. All hits, therefore, by definition are biologically meaningful in such a screen. In our case, we were interested in identifying perturbagens capable of modulating HCV replication. Because the level of HCV replication can now be assayed, use of the forward chemical genetics approach is now possible.
To efficiently determine whether small molecules exert a certain biological effect in a suitable assay system, rapid high-throughput screening (HTS) methods have been developed. Using the high-density 384-well plate format, it is possible to efficiently and successfully conduct highthroughput phenotypic screens on mammalian cell constructs bearing reporter genes, such as those found in HCV replicon systems, with large libraries of small molecules. 7 Thus far, however, efficient HTS for HCV drug discovery has remained elusive. Although HCV replicon systems have been established as efficient cell-based screening platforms, no true HTS methods utilizing these systems have been described to date. Experimental barriers have included low signal-to-background ratio and the added burden of complex processing steps, such as washing, aspiration, and lysis prior to signal read-out.
The subgenomic Huh7/Rep-Feo HCV replicon cell line 8 appears to be particularly well suited to automated HTS methods, so it was selected for further assay development. This replicon was derived from a chimpanzee infectious clone (strain HCV-N, genotype 1b). In this replicon, the structural genes have been replaced by a reporter gene. The chimeric reporter gene Feo encodes the firefly luciferase protein fused in-frame with neomycin phosphotransferase. This Huh7/Rep-Feo cell supports high levels of autonomous HCV RNA replication because it was derived from the HCV-N strain, which carries an adaptive mutation in NS5A that confers highlevel replication in tissue culture. Furthermore, the level of luciferase correlates well with levels of HCV RNA production, so that luciferase can be used as a reliable surrogate marker for HCV replication. The use of luciferase as a reporter permits quantitative and highthroughput detection of HCV replication levels. The specific use of firefly luciferase makes this replicon especially well-suited for automation, because the luciferase reagent can be added directly to the cell culture system prior to signal detection without the need for cell lysis, washing, or aspiration.
In the course of our attempts to apply chemical biology to the elucidation of the regulation of HCV replication, we first optimized the Huh7/Rep-Feo replicon for the 384-well microplate format and then used it to screen a library of known bioactive compounds using automated technology. After identifying several molecules capable of either stimulating or inhibiting HCV replication in this primary screen, we then validated our hit compounds in secondary screens. Here we describe a simple, reproducible, and reliable cell-based HTS assay system using a HCV replicon model to identify small molecules that regulate HCV replication and further characterize the antiviral properties of the HMG-CoA reductase inhibitors, as well as the proviral properties of corticosteroids.
Materials and Methods

HCV Replicon System-Primary Screening
Cells were propagated in Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) supplemented with 1% penicillin-streptomycin, and 500 g of Geneticin (Invitrogen Corp., Carlsbad, CA) /mL. Cells were cultured in a 37°C, 5% CO 2 -humidified incubator for all experiments. To decrease day-today variability in the assay, a large homogenous population of subconfluent cells was passaged so that a similar lot of cells could be used throughout the HTS assay.
Optimization of Huh-7/Rep-Feo Cells for the 384-Well Plate Format
The Huh7/Rep-Feo cells were first optimized for the 96-well plate format. Peginterferon-alfa-2b (PEG-Intron; Schering Corp., Kenilworth, NJ) was used as a positive control for inhibition. Cells were seeded at densities of 5000 and 10,000 cells/well in 100 L of medium in 96-well plates. The cells were allowed to attach overnight (ϳ24 hours) before addition of PEG-IFN at various concentrations (day 0). The plates were then incubated further, and measurements were taken at 24, 48, and 72 hours. At each time point, the plates were equilibrated at room temperature, an equal volume of Bright-Glo reagent (Promega, Madison, WI) was added, and the plates were read in a LumiCount (Packard BioScience Company, Downers Grove, IL) luminometer. For the 384-well plate format, cells were seeded at densities of 1000, 2500, and 5000 cells/well in 30 L of medium. The remainder of the experiment was carried out as described for 96-well plates. Results were expressed as the mean of 3 replicate wells.
Primary Screening-HTS
Information about the library of known bioactive compounds that was screened and the general automated HTS protocol is available at http://www.broad.harvard.edu/ chembio/index.html.
Based on the results of optimization experiments in the 384-well plate format, the general HTS protocol was adapted as follows. Unless otherwise indicated, cells were incubated at all times in a humidified environment with 5% CO 2 at 37°C. The assay was initiated by plating 30 L of medium containing 2000 cells/well into white 384-well opaque-bottom plates (Nunc, Rochester, NY) using an automated plate filler (Bio-Tek Filler; Winsooki, VT) and allowing the cells to adhere for 24 hours. One hundred nL of compound stock solutions in DMSO was transferred from stock plates into the 384-well assay plates using an automated pin-based compound transfer robot (CyBio CyBi-Well vario; Woburn, MA). The final compound concentration in each well was estimated to be approximately 10 -50 M, with most compounds at 33 M. The wells contained 0.33% DMSO by volume. The cells were then incubated for another 48 hours. The luminescent signal from each plate was detected using an automated plate reader (Perkin-Elmer Envision 1; Wellesley, MA). This screen was performed in duplicate. For negative controls, entire DMSO-treated control plates were employed, in addition to DMSO-only control wells that were incorporated into each compound assay plate. The cells were assayed for luciferase activity using the Bright-Glo Luciferase assay system (Promega), following the manufacturer's instructions. As a counter-screen, cell viability was assessed using the CellTiterGlo Luminescent cell viability assay (Promega) following the manufacturer's instructions.
Computational Data Analysis-Primary Screening
For each replicate, a mock-treatment distribution based on the total population of mock (DMSO) controls in that replicate was built. Each compound was independently assigned a sign (ie, "ϩ" or "Ϫ") Z-score. Z-scores are calculated by dividing each background-subtracted, compound-treated well by the global standard deviation. A global standard deviation of the background-subtracted, mock-treated wells is calculated over the entire experiment. This distribution was determined to be consistent with experimental noise observed under cell-based assay conditions. The resulting collection of continuousvalued Z-scores represents the primary data set to be used for further analysis. The composite Z-score was calculated as a vector projection of each Z-score in duplicate onto an imaginary line of perfect reproducibility. Reproducibility is the cosine of the angle between each Z-score and that imaginary line; it is dimensionless and ranges from -1 to ϩ1. For analyses dependent upon discrete (ie, binned) outcome states, composite Z-score data were further subjected to a threshold that resulted in each measurement being scored as a high-or low-signal outlier, or as a nonoutlier, from the mock-treatment distribution, based on the possibility that the measurement could be explained by assay noise (P noise Ͻ .0005).
The primary data were analyzed using the commercial software packages Pipeline Pilot (SciTegic, San Diego, CA) and SpotFire (SpotFire, Inc., Somerville, MA). The means of the negative, DMSO-only controls were considered the zero point. For the bioactives library, compounds were considered hits for inhibiting replication if they had a composite Z-score of ϽϪ5.14 in the reporter gene screen, a reproducibility of Ͼ0.9 or ϽϪ0.9 in that screen, and a composite Z-score of ϾϪ2.57 in the cell viability screen. Compounds were considered hits for promoting replication if they had a composite Z-score of Ͼ5.14 in the reporter gene screen, a reproducibility of Ͼ0.9 or ϽϪ0.9 in that screen, and a composite Z-score of Ͻ2.57 in the cell viability screen.
HCV Replicon System-Secondary Assays
For validation, OR6 cells stably harboring the full-length genotype 1 replicon, ORN/C-5B/KE 9 were used to examine compound activity in a more authentic viral polyprotein context. This replicon was derived from the 1B-2 strain (strain HCV-O, genotype 1b), in which the Renilla luciferase gene is introduced as a fusion protein with neomycin to facilitate the monitoring of HCV replication. This construct contains a tissue culture adaptive mutation in the NS3 region. Cells were cultured in an identical manner to the Huh7/Rep-Feo cells.
Secondary Assays-Hit Validation
Several hits from primary HTS, as well as functionally related compounds, were purchased from Sigma (St. Louis, MO), Calbiochem (San Diego, CA), and Microsource (Gaylordsville, CT). Proviral compounds included (1) corticosteroids-triamcinolone acetonide, prednisolone, dexamethasone, and methylprednisolone, (2) PPAR-gamma ligands-N-(9-fluorenylmethoxy-car- Ten mM of stock solutions of the individual compounds to be tested was prepared in the appropriate solvent (DMSO, ethanol, or H 2 O, according to the manufacturer's information) and stored at Ϫ20°C.
Cells were seeded into 96-well plates at a density of 2000 cells/well in 100 L of medium. The cells were incubated for 24 hours at 37°C to obtain the optimal level of adherence. Solutions of candidate hit compounds were added to wells to achieve final concentrations of 0.1, 1, 10, 50, and 100 M. The final concentration of DMSO or ethanol in every well was 1% or less by volume. Mock solutions were used as a negative control. PEG-IFN and ribavirin were used as positive controls at various concentrations, alone and in combination. The plates were then incubated at 37°C with 5% CO 2 for 48 hours before they were analyzed. Luminescent signal was generated using the Renilla luciferase assay kit (Promega) according to the manufacturer's instructions. Signal was then detected using a LumiCount (Packard BioScience Company) luminometer. Cell viability was assessed using CellTiter-Glo (Promega), following the manufacturer's instructions. All experiments were performed in triplicate.
Secondary Assays-Data Analysis
Values were presented as a percentage of mock treated control, which was arbitrarily set at 100%. Data were expressed as the mean Ϯ SD. Results were analyzed using a paired t test to determine the significance of observed differences between the values of control and individual concentrations and were considered significant if the P values were less than .05. Synergy calculations were performed using CalcuSyn (Biosoft; Cambridge, England).
Results
Optimization of Huh-7/Rep-Feo Cells for the 384-Well Plate Format
HCV replication in the subgenomic replicon cell model was tightly coupled to host cell growth conditions. 10, 11 Experimentally, HCV RNA replication in the subgenomic replicon cell increased progressively over time, followed by a sharp decline when the cells reached 70% confluence. There was a good linear relationship between cell number and luciferase signal in test tube (data not shown). Inasmuch as the wells of microplates have a small culturable surface, the Huh7/Rep-Feo cells were optimized for both the 96-well and 384-well plate formats using PEG-IFN as a positive control. For 96-well plates, the signal-to-background (S/B) ratio was very high (over 100) when cells were incubated at a concentration of 5000 cells/well at culture day 0. The S/B ratio progressively increased over time, peaking at culture day 2 and then decreased from culture day 3 onward, when cells reached over 70% confluence. The antiviral activity of PEG-IFN progressively increased over time. On the other hand, although the initial S/B ratio at an inoculation 
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concentration of 10,000 cells/well was higher than at 5000 cells/well, there was no significant increase of the S/B ratio over time (data not shown). For 384-well plates, the S/B ratio at an inoculation concentration of 1000 cells/well progressively increased over time, with a large standard deviation. The S/B ratio at an inoculation concentration of 5000 cells/well peaked at culture day 1, when an optimum level of confluence was reached. The S/B ratio at an inoculation concentration of 2500 cells/ well was ideal, with the optimal S/B ratio achieved at culture day 2 ( Figure 1 ). We therefore selected 2500 cells/well at culture day 2 for subsequent studies. Figure 2 shows a graphical representation of the primary HTS results. Many compounds appeared to have strong antiviral activity when the luciferase reporter gene assay alone was considered. When these results were analyzed in conjunction with those of the cell viability assay, however, most of the potential antiviral hit compounds were cytotoxic and, therefore, false positives. For that reason, it is imperative to perform the primary HTS as a 2-dimensional assay with both the level of HCV replication and cell viability measurements, in order to minimize confounding from increased luciferase signals due to increased cell titer and decreased luciferase signals due to decreased cell titer.
Primary Screening (HTS) Results
Using the data analysis and hit selection criteria outlined in Materials and Methods, we identified 21 antiviral compounds that inhibited HCV replication and 28 proviral compounds that increased HCV replication ( Table  1) . The respective hit rates of 0.8% and 1.1% are consistent with hit rates for other biological screens performed using this library.
Proviral compounds included steroids (estrone, triamcinolone), coumarins (xanthylentin, dihydrobliquin, and marmesin), flavones, and a PPAR-gamma ligand (N-9-fluorenylmethoxycarbonyl-L-leucine). Antiviral compounds included an HMG-CoA reductase inhibitor (atorvastatin), a beta-adrenergic blocker (propranolol), a calcium channel blocker (tetrandrine), a phosphodiesterase (PDE) inhibitor (MY-5445), and a p38 MAP kinase inhibitor (SB 203580). The finding of antiviral activity associated with the HMG-CoA reductase inhibitor was of particular interest, as the HMG-CoA reductase inhibitor lovastatin has recently been shown to exhibit anti-HCV activity. 12 Although corticosteroids have been assumed to increase HCV replication by means of host immunosuppression, they have not been reported to be a specific proviral agent for HCV independent of their general immunosuppressive activity. 13 SB-203580 has been previously reported to have mixed effects on HCV replication. 14, 15 
Anti-HCV Activity of PEG-IFN and Ribavirin in the OR6 Replicon System
We tested PEG-IFN and ribavirin at various concentrations, alone and in combination, as it has been reported that OR6 cells bearing a genome-length HCV RNA replicon were sensitive to these agents. 9 The IC 50 of R-CompZ, composite Z-score for reporter gene assay; C-CompZ, composite Z-score for cell viability assay.
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PEG-IFN was between 0.007 and 0.03 ng/mL. The IC 50 of ribavirin was between 50 M and 100 M ( Figure 3A) . As previously reported, the combination of ribavirin with PEG-IFN showed synergy ( Figure 3B ). These results demonstrate that HCV RNA replication in OR6 cells is highly sensitive to PEG-IFN, ribavirin, and a combination of both agents.
Hit Validation
Several proviral and antiviral hit compounds identified in the primary screen were selected for further validation on the basis of commercial availability and clinical interest. In order to examine compound activity in a more authentic viral polyprotein context, the validation assays were carried out using the OR6 full-length genotype 1b replicon. Multiple concentrations of each compound were used in order to generate an adequate dose-response curve. In addition to the actual hit compounds themselves, other compounds from the relevant compound classes were subjected to secondary validation assays.
Proviral compounds. Triamcinolone was confirmed to increase HCV replication in the full-length HCV replicon system (Figures 4A and B) . Other corticosteroids (prednisolone, dexamethasone, and methylprednisolone) also increased HCV replication ( Figures 4A and  B) . The PPAR gamma ligand, N-(9-fluorenylmethoxycarbonyl)-L-leucine, which was identified as a proviral hit in the primary screen, showed mild proviral activity. Troglitazone showed proviral activity at 1 and 10 M. The decreased luciferase signal at 50 M and above was due to cytotoxicity. Clofibrate, a PPAR alpha ligand, did not show a proviral effect. The coumarin compounds did not demonstrate any significant proviral activity (data not shown).
Antiviral compounds. Although the PDE inhibitor, MY5445, decreased the luciferase signal in a doserelated manner, it displayed significant cytotoxicity. Another PDE inhibitor in the bioactives library, trequinsin, was not identified as a hit in the primary screen, where it was tested at a concentration of 33 M and found to be cytotoxic. It did, however, display antiviral activity at the lower concentrations of 1 and 10 M in the validation assay, with significant cytotoxicity only at the higher concentrations of 50 and 100 M (Figures 5A and B) .
The p38 MAPK inhibitor, SB 203580, exhibited antiviral activity at a concentration of 10 M and cytotoxicity at higher concentrations ( Figures 5C and D) . Other MAPK inhibitors, such as SB 202109, were inactive in both the primary screen and in the secondary assay (data not shown).
The antiviral effect of the calcium channel blocker, tetrandrine, could not be evaluated because of cytotoxicity in the secondary assay ( Figures 5E and F) . Other 
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calcium channel blockers, such as verapamil and nifedipine, did not exhibit antiviral activity in either the primary screen or the validation assay (data not shown).
Strikingly, each of the HMG-CoA reductase inhibitors, except for pravastatin, significantly decreased HCV replication in a dose-related manner, with IC 50 values between 1 and 10 M. Atorvastatin, simvastatin, and fluvastatin demonstrated strong antiviral effects. Lovastatin, previously reported as an inhibitor of HCV replication, 12 and mevastatin were weakly inhibitory. Lovastatin was significantly cytotoxic at 10, 50, and 100 M. Mevastatin was not cytotoxic. Pravastatin showed very weak antiviral activity, with only 30% inhibition at 100 M ( Figure 6 ).
Discussion
Using a subgenomic HCV replicon model, we have established a rapid, reliable, and reproducible cell-based HTS assay system to identify regulators of HCV replication. After first identifying several bioactive small molecules capable of modulating HCV replication in the primary HTS, we verified these hit compounds using a full-length replicon cell line in the secondary validation assay. This method represents an efficient system for the detection of novel compounds, applicable for both academic and pharmaceutical purposes.
In order to successfully develop and execute an efficient, rapid, and reproducible cell-based HTS assay in the field of anti-HCV drug discovery, one must have access to (1) a high-density, automated screening technology platform, (2) a large and diverse collection of appropriate perturbagens, and (3) an accurate and reliable reporter system, which, in this case, was an HCV replicon line that replicates at high levels and harbors a tractable reporter gene.
Traditional HTS techniques using a 96-well plate have been shown to be less efficient at screening very large libraries than more high-density formats. Moreover, 
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small assay volumes are required for maximum efficiency, in order to minimize expense, space requirements, reagent consumption, and experimental time. The advancement of HTS technologies has made it possible to execute cell-based HTS with 384-well and even 1536-well plates. Use of automated methods for plate filling, compound transfer, and plate reading further maximizes efficiency. With the assistance of sophisticated software tools, screening data can be rapidly analyzed in an automated fashion. [5] [6] [7] In addition to an efficient screening platform, large, diverse libraries of small molecule pertubagens appropriately formatted for this platform are required. The known bioactives library, a collection of 2568 known and proven bioactive molecules, including FDA-approved drugs, was the library screened in this report. Also available were commercially available combinatorial chemistry libraries and several diversity-oriented synthesis (DOS) libraries. One of these DOS libraries, Project Kornberg (a library of over 8000 DOS molecules that links chemists from multiple research groups throughout the US), was also screened using the methodology developed in this article. These results are the subject of a separate report.
Finally, a cell line carrying an accurate and reliable reporter is needed to efficiently screen large small-molecule libraries. To this end, the selection and optimization of the most appropriate HCV replicon cell line is very important. To successfully perform high-density HTS using 384-well plates, several characteristics of an HCV replicon cell line must be taken into account, such as RNA replication levels carrying an easy read-out reporter gene and host cell growth characteristics.
We selected the subgenomic Huh7/Rep-Feo replicon cell line because of its robust level of replication. 8 The level of HCV replication appears to be very high in this replicon cell line, although the precise comparison of replication levels between various replicon cell lines is difficult because of differing conditions in different laboratories. 16 -19 We chose a replicon bearing the firefly luciferase gene because it can be easily measured, is very sensitive, and has a suitably long half-life. 8, 20 Indeed, we obtained a high S/B ratio (Ͼ100) in the 384-well plate format, ensuring the suitability of this system for highdensity HTS assays.
To facilitate detection of HCV replication, several replicon cell lines that carry reporter genes, such as betalactamase, 21 luciferase, 8, 9, 20 and secreted alkaline phosphatase (SEAP), 22, 23 have also been developed. In fact, a cell-based HTS assay using 384-well plates has been developed with an HCV replicon bearing a beta-lactamase reporter gene. 24 However, this replicon model has several disadvantages. There is a relatively low signal to background. Moreover, additional processing is required to suppress the high background signal. Finally, because the cell line was transiently transfected, it requires extensive preparation prior to screening. Renilla luciferase has also been used as a reporter gene, but is not an ideal choice because of its very short signal half-life. Moreover, aspiration and lysis processing steps must be carried out prior to signal detection. 9 On the other hand, replicon cell models bearing a SEAP reporter do not require aspiration and lysis steps. 22, 23 These systems, however, either require another viral protein, such as tat, to express the reporter protein or require the action of NS3/4A-specific protease activity. 22, 23 Replicons bearing firefly luciferase reporter genes, therefore, appear to be better suited for use in HTS assays.
Many small molecules are cytotoxic, and hepatocyte replicon cell lines are highly sensitive to cytotoxic or cytostatic agents. 8, 20 Cytotoxic effects can be mistaken for antiviral activity by decreasing luciferase signal merely by decreasing cell viability and not by decreasing HCV RNA replication, leading to false-positive results. In fact, when we confined our analysis to the reporter gene assay alone, our hit rates were very high, primarily due to falsepositive results from cytotoxic compounds. We therefore perform both the reporter gene assay and a cell viability assay in parallel in our primary HTS, a step we view as essential. This counter screen was executed in order to minimize confounding from increased or decreased luciferase signal due to increased or decreased cell viability, respectively.
To verify hit compounds identified from primary screening, an appropriate secondary assay must be performed. We used the subgenomic Huh7/Rep-Feo replicon cell line in our primary screen because of its simplicity, rapidity, robustness, and reproducibility. Its disadvantages include its lack of structural proteins, its specific adaptive mutation, and its firefly luciferase reporter gene. By using a subgenomic replicon, the influence of structural proteins on the antiviral activity of compounds cannot be probed. Furthermore, a cell culture adaptive mutation may affect the biochemical properties of a protein by altering its sensitivity to an antiviral drug. 3, 4 Compounds that specifically inhibit firefly luciferase activity can be identified as false-positive antiviral hits. For instance, pifithrin, an antiviral hit in our primary screen, inhibits firefly luciferase, but not Renilla luciferase. 25 In the secondary screen, we validated primary hits using a full-length OR6 replicon, 9 thereby ensuring validation in a more authentic viral polyprotein context. This full-length replicon also possesses a cell cultureadaptive mutation and a reporter gene distinct from those found in the subgenomic Huh7/Rep-Feo replicon, thereby minimizing confounding from those factors.
One of the limitations of high-throughput screening is that the generation of adequate dose-response curves for each of the compounds tested in a large primary screen would overwhelm the capacity of even the best screening technology platform by the sheer number of data points generated. Although screening at a single fixed concen-tration per compound may lead to missing potential hits, it is much more efficient generating the dose-response data only for those compounds identified as hits. We conducted secondary validation screens to generate adequate dose-response curves for our hit compounds. We also performed cell viability assays in our secondary screens to minimize confounding from cytotoxicity.
Corticosteroids have been reported to promote HCV replication. It is thought that they exert their effects via host cellular immunosuppression. 13 However, our results demonstrate the direct proviral effect of corticosteroids in both a subgenomic and a full-length HCV replicon system. These data suggest that corticosteroids are capable of promoting HCV replication independent of their host immunosuppressive activity. Further study of the direct regulation of HCV replication by corticosteroids is warranted.
Strikingly, the statins were found to exhibit powerful antiviral effects. Lovastatin has been shown in an independent model to decrease HCV replication. 12 These compounds are inhibitors of HMG-CoA reductase and shut down cholesterol biosynthesis by preventing the formation of mevalonate from 3-hydroxy-3-methyl-glutaryl CoA. In addition to lowering intracellular levels of sterols, statins also reduce levels of isoprenoids, which are derived from mevalonate. Isoprenoids such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate serve as lipid attachments for a variety of intracellular signaling molecules. It has been reported that inhibition of geranylgeranylation, rather than the synthesis of cholesterol itself, is responsible for the inhibition of HCV RNA replication. 12, 26 All statins except pravastatin showed good dose response in the secondary assays, with IC 50 values from 1-10 M. The HMG-CoA reductase inhibitors therefore appear to demonstrate potential as antiviral agents.
Recently, Ikeda et al reported anti-HCV profiles of 5 different statins using the OR6 replicon system. They found that fluvastatin exhibited the strongest anti-HCV activity, whereas atorvastatin, simvastatin, and lovastatin had moderate-to-mild anti-HCV activity. Pravastatin did not have significant anti-HCV activity. 27 However, our results show that the anti-HCV activity of the statins in order of decreasing potency was simvastatin, fluvastatin, atorvastatin, mevastatin, lovastatin, and pravastatin. It is likely that the IC 50 of simvastatin, 1.6 M, was higher than Ikeda's because our data were obtained at only 48 hours after treatment, as opposed to 72 hours in the Ikeda study. Pravastatin also had anti-HCV activity, although it was very weak (IC 50 : 238.5 M, data not shown). Furthermore, as with the study of Ikeda, the anti-HCV effect of the statins, including that of pravastatin, was rescued by addition of geranylgeraniol (data not shown). Because the HCV genome does not encode a geranylgeranylated protein, we hypothesize that a host geranylgeranylated protein must play an important role in HCV replication and that inhibition of the geranylgeranylation of this protein represents a potential strategy for blocking HCV replication. Thus, for statins to exert their anti-HCV effects, they must deplete mevalonate sufficiently to lower the cellular pools of geranylgeranyl pyrophosphates in the replicon cell lines. We speculate that this indirect mechanism of action explains an anti-HCV IC 50 for statins in the micromolar range, in contrast to their IC 50 for HMG-CoA reductase in the nanomolar range. 12, 28 Potential reasons for pravastatin's observed weaker activity include its higher hydrophilicity compared to the other statins and its lack of metabolism by the cytochrome P450 system. 29 Although we verified several hit compounds, such as the corticosteroids and the HMG-CoA reductase inhibitors, our validation assays revealed some false positives from our primary screening. Tetrandrine and MY-5445 were antiviral hits in the primary screen that were found to be false positives with significant cytotoxicity in secondary, but not primary, screening. This phenomenon was also observed for lovastatin. These false-positive results may be due in part to the lack of HCV structural proteins in our primary screening system. For example, the expression of HCV core protein has been reported to affect Fas-mediated apoptosis depending on environmental conditions. 30 Thus, it is possible that HCV core, in the presence of small molecules, could lead to apoptosis and cytotoxicity. These findings demonstrate that validation of primary screening results with subgenomic replicon systems should be performed with full-length replicon systems in order to totally assess the potential interactions of these compounds in the authentic viral protein context. Although our cell-based HTS system represents an effective screening method for identification of potential antiviral agents, there are potential limitations to use of the Huh7/Rep-Feo replicon cell line, which is based on a subgenomic, not full-length, genotype 1b clone. By using the full-length OR6 replicon cell line for our confirmatory secondary assays, we have addressed one particular limitation. With regard to genotype, recent description of a bona fide infectious HCV cell line propagating genotype 2 virus 31,32 will permit assessment of the generalizability of the inhibitory action of these agents against other HCV genotypes. To date, the vast majority of HCV replicons have been developed in Huh7 cells, which appear to be uniquely permissive for these studies. With the eventual development of successful replication models in other hepatocyte cell lines, further testing of these compounds in such lines will also be of interest.
In summary, we have developed a rapid, reliable, reproducible, and validated cell-based HTS method to identify positive and negative regulators of HCV replication. This method can be used not only to identify putative antiviral agents but also cellular regulators of replication. The compounds identified by these screens can be used not
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only for medicinal effect but also as a productive approach to the characterization of key viral-host interactions critical to viral replication.
